What is Genesis Biosystems?
Genesis Biosystems operates as a premier developer of advanced aesthetic technologies, specializing in high-efficacy skin rejuvenation systems. The company's flagship offering, DermaFrac, represents a cornerstone of its product portfolio, providing practitioners with a versatile platform for customized dermatological procedures. By prioritizing clinical safety, procedural efficacy, and rigorous quality standards, Genesis Biosystems has established itself as a trusted partner for aesthetic practitioners worldwide. The firm distinguishes itself not only through hardware innovation but also through comprehensive practitioner training and ongoing clinical support, ensuring that end-users achieve optimal skin health outcomes. This commitment to the intersection of medical science and aesthetic beauty has allowed the company to maintain a competitive edge in a rapidly evolving, high-demand industry.
How much funding has Genesis Biosystems raised?
Genesis Biosystems has raised a total of $114K across 1 funding round:
Debt
$114K
Debt (2021): $114K with participation from PPP
Key Investors in Genesis Biosystems
PPP
Public-Private Partnership
What's next for Genesis Biosystems?
With the successful acquisition of $114K, Genesis Biosystems is poised to enter a new phase of organizational maturity. The strategic deployment of this capital will likely focus on expanding the company's research and development pipeline to introduce next-generation skin treatment modalities. Furthermore, the late-stage nature of this financing suggests a concerted effort to optimize global supply chain logistics and enhance market distribution channels. As the aesthetic industry continues to shift toward non-invasive, high-performance solutions, Genesis Biosystems is strategically aligned to capture additional market share. Future growth initiatives will likely emphasize the integration of digital health tools into their existing product ecosystem, further empowering practitioners to deliver data-driven, personalized patient care on a global scale.
See full Genesis Biosystems company page
